FINALTO-S.P.V.-LTD
2.8.2021 19:43:08 CEST | Business Wire | Press release
Finalto S.P.V. Ltd, the consortium led by Barinboim Group and backed by Leumi Partners Limited and Menora Mivtachim Group, together with key members of the Finalto Business' management team (together the "Consortium"), welcomes the announcement by Playtech plc (“Playtech”) confirming its recommendation that shareholders vote in favour of the Consortium’s binding agreement for Finalto Group (“Finalto) (the “Binding Agreement”).
Playtech announced today that following its engagement with Gopher Investments (“Gopher”) over the past three weeks, it has not received responses from Gopher to a number of its questions and therefore “Playtech has not yet been able to achieve the necessary clarity on Gopher's ultimate ownership and funding structure, source of funds or ability to obtain the required regulatory clearances ” .
Shareholders should ask why Gopher continues to hide and should also be suspicious of Gopher’s credibility, particularly given that disclosure is crucial when buying a highly regulated business. Furthermore, the firm associated with Gopher, TT Bond Partners, is a small boutique brokerage that raises money from Chinese investors. Gopher’s behaviour has not been well received by the market; since it first announced its interest, Playtech’s share price has fallen by nearly 17%1 .
The Consortium’s Binding Agreement for Finalto offers considerable value and certainty and puts an end to the arduous 18-month sale process
- Voting in favour of the Consortium’s Binding Agreement, which has been unanimously supported by Playtech’s board of directors, ensures Playtech receipt of the considerable sale proceeds soon allowing it to focus on its core gambling business. The Binding Agreement was agreed after beating other rival bidders in a lengthy, arduous and transparent sale process that was run by UBS and offers far greater certainty that the transaction will complete and pass the stringent regulatory approvals.
- The level of volatility and risk that the Finalto business is subject to and the performance headwinds that it faces, led to the ultimate price that was agreed and Playtech recommending the Consortium’s Binding Agreement to acquire Finalto. Indeed, in the original circular to shareholders, Playtech itself comments on Finalto’s tumultuous performance in 2021, underlining the businesses underperformance relative to prior years.
- If shareholders vote against the Binding Agreement the Consortium will fall apart. Should this happen, shareholders need to reflect on the likelihood that Gopher would follow through on its indicative interest at the level they purport to offer for Finalto.
- Voting in favour of the Consortium removes the considerable risk, delay and additional costs associated with yet another sale process, which would not be concluded until late 2022 at the earliest. Such a delay would be considerably destabilising to the Finalto business, which has already been subject to a lengthy sale process and significant market speculation.
- From the outset of the transaction, the Consortium’s Binding Agreement was and remains fully financed by the three blue chip multinationals comprising the Consortium and a reputable senior lender. Completion is subject to Playtech’s shareholders’ approval and final regulatory approvals only, which the Consortium is already six months into and has submitted the required arduous change of control paperwork to each of the regulators in multiple jurisdictions.
- The Consortium welcomes shareholders and proxy advisors ISS and Glass Lewis to engage with it in order to answer any questions regarding its Binding Agreement, which it believe provides the best value to Playtech.
The Consortium urges shareholders to follow Playtech’s Board recommendation and vote in favour of its Binding Agreement to acquire Finalto at the General Meeting due to take place on 18 August 2021.
The Original Circular, the Supplementary Circular and the Notice of Adjourned General Meeting are available on Playtech's website at www.investors.playtech.com/shareholder-information/general-meeting.aspx . Shareholders who have already submitted their proxy electronically at www.investorcentre.co.uk/eproxy and wish to change their voting instruction, may do so by submitting a revised Form of Proxy electronically at www.investorcentre.co.uk/eproxy .
The Consortium’s previous announcements are available here (7 July 2021) and here (9 July 2021).
-ENDS-
About the Consortium
The Consortium is a company incorporated in Israel, established for the purpose of acquiring the Finalto Business. The Consortium is being funded by a group consisting of Barinboim Group, Leumi Partners Limited and Menora Mivtachim Group and by senior secured debt financing from The Phoenix Insurance Company Limited and certain of its affiliates. The Consortium will be supported by key members of the Finalto Business' management team that will transfer with the Finalto Business, including Ron Hoffman (Chief Executive Officer of the Finalto Business) and Liron Greenbaum (Chief Operations Officer of the Finalto Business).
Barinboim Group is a private equity and venture capital firm based in Tel Aviv. Barinboim Group invests in companies operating in the media sectors.
Leumi Partners Limited is the merchant and investment banking arm of Bank Leumi (TASE: LUMI), one of the two largest banking groups in Israel. Leumi Partners Limited is based in Tel Aviv and offers direct equity investment in sectors such as technology media and telecom, consumer & retail, and healthcare. Leumi Partners Limited's line of business includes conducting investments and providing services such as underwriting, financial analysis and research, strategic advice, mergers & acquisitions, and raising equity and debt.
Menora Mivtachim Group is one of Israel's five largest insurance & finance groups. The group specializes in asset management, manages the largest pension fund in Israel - and is the largest General Insurer in Israel and the market leader in Motor Insurance sector. The group operates through its subsidiaries, in all sectors of Life Insurance, Long/Mid/Short -Term Savings, General Insurance and Health Insurance. In addition, the group is active in the capital markets and finance sectors, including, Financial Portfolio Management, Underwriting and worldwide real estate investments.
1 Source: Capital IQ. July 30 close price over July 2 close price
View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005628/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alipay Launches Next-Generation AI Payment Infrastructure, Debuts AI Wallet and Token Pay to Power Agentic Economy26.5.2026 17:20:00 CEST | Press release
Alipay today introduced its full-stack AI payment solution to partners across industries, ranging from AI companies to traditional retailers, and debuted two new services — the world’s first AI Wallet and Token Pay — to support the agentic economy’s rapid growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526337824/en/ Alipay Unveils Next-generation AI Payment Infrastructure This launch extends Alipay's next-generation AI payment infrastructure, building on its consumer-facing product Alipay AI Pay and its business-facing AI payment processing product. “While the essence of commerce remains unchanged in the age of AI, the emergence of AI agents is reshaping everything. Drawing on 22 years of technological expertise and commercial know-how, Alipay is building a new generation of AI payment services to accelerate the growth of the agentic commerce ecosystem,” said Cyril Han, CEO of Ant Group. AI Wallet: Giving Users Vis
Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 202626.5.2026 17:00:00 CEST | Press release
Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 Daiichi Sankyo Europe’s commitment to "care for every heartbeat" is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. Daiichi Sankyo Europe (DSE) is pleased to announce its extensive scientific presence at the European Atherosclerosis Society (EAS) Congress 2026. The presentation of 15 abstracts, comprising both clinical trial analyses and real-world evidence, underscores the company's sustained investment
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
